Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis

[1]  Lei Wu,et al.  Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis , 2010, British journal of pharmacology.

[2]  P. Schafer,et al.  Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. , 2009, Journal of medicinal chemistry.

[3]  D. Spina,et al.  PDE4 inhibitors: current status , 2008, British journal of pharmacology.

[4]  P. Anand,et al.  Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. , 2007, Arthritis and rheumatism.

[5]  J. Beavo,et al.  Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. , 2007, Annual review of biochemistry.

[6]  D. Spina,et al.  PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast , 2007, International journal of chronic obstructive pulmonary disease.

[7]  Y. Shimizu,et al.  Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059. , 2007, European journal of pharmacology.

[8]  Neil Upton,et al.  Further validation of LABORAS™ using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration , 2006, Journal of Neuroscience Methods.

[9]  Kam Y. J. Zhang,et al.  Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.

[10]  S. Reiken,et al.  Phosphodiesterase 4D Deficiency in the Ryanodine-Receptor Complex Promotes Heart Failure and Arrhythmias , 2005, Cell.

[11]  M. Giembycz.  Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. , 2005, Current opinion in pharmacology.

[12]  Ana Martínez,et al.  Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors , 2005, Medicinal research reviews.

[13]  G. Baillie,et al.  Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[14]  G. Molostvov,et al.  The effects of selective cytokine inhibitory drugs (CC‐10004 and CC‐1088) on VEGF and IL‐6 expression and apoptosis in myeloma and endothelial cell co‐cultures , 2004, British journal of haematology.

[15]  M. Feldmann,et al.  Impact of VIP and cAMP on the regulation of TNF-α and IL-10 production: implications for rheumatoid arthritis , 2003, Arthritis research & therapy.

[16]  J. Beavo,et al.  Cyclic nucleotide research — still expanding after half a century , 2002, Nature Reviews Molecular Cell Biology.

[17]  N. Zvaifler,et al.  Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. , 2002, Arthritis and rheumatism.

[18]  J. Bourguignon,et al.  Anti-TNF-alpha properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4- inhibiting properties. , 2001, Biochemical and biophysical research communications.

[19]  J. Barsig,et al.  In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. , 2001, The Journal of pharmacology and experimental therapeutics.

[20]  R Remie,et al.  Validation of a new system for the automatic registration of behaviour in mice and rats , 2001, Behavioural Processes.

[21]  M. Teixeira,et al.  Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis. , 2000, European journal of pharmacology.

[22]  F. Antoni.  Molecular Diversity of Cyclic AMP Signalling , 2000, Frontiers in Neuroendocrinology.

[23]  D. Schrier,et al.  Effects of the phosphodiesterase inhibitor rolipram on streptococcal cell wall-induced arthritis in rats. , 1999, International journal of immunopharmacology.

[24]  M. Foster,et al.  Potential of phosphodiesterase type of IV inhibitors in the treatment of rheumatoid arthritis. , 1998, IDrugs : the investigational drugs journal.

[25]  M. Feldmann,et al.  Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. , 1997, Journal of immunology.

[26]  P. Barnes,et al.  Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. , 1995, Molecular pharmacology.

[27]  A. Hatzelmann,et al.  PDE isoenzymes as targets for anti-asthma drugs. , 1995, The European respiratory journal.

[28]  D. Yarnall,et al.  Anti‐inflammatory activity of phosphodiesterase (PDE)‐IV inhibitors in acute and chronic models of inflammation , 1995, Clinical and experimental immunology.

[29]  E. F. Smith,et al.  Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. , 1994, International journal of immunopharmacology.

[30]  P. Morris,et al.  Rapid assessment of islet cell viability by MTT assay after cold storage in different solutions. , 1994, Transplantation proceedings.

[31]  S. Endres,et al.  The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. , 1993, International journal of immunopharmacology.

[32]  P. Zabel,et al.  OXPENTIFYLLINE IN ENDOTOXAEMIA , 1989, The Lancet.

[33]  M. Feldmann,et al.  INHIBITORY EFFECT OF TNFα ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS , 1989, The Lancet.

[34]  M. Feldmann,et al.  Cytokine production in culture by cells isolated from the synovial membrane. , 1989, Journal of autoimmunity.

[35]  Konstantinos Tziomalos,et al.  Curr Med Res Opin , 2009 .

[36]  B. Strober,et al.  An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. , 2008, Current medical research and opinion.

[37]  Richard O. Williams.  Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha. , 2007, Methods in molecular biology.

[38]  F. Brennan,et al.  Preparation of mononuclear cells from synovial tissue. , 2007, Methods in molecular medicine.

[39]  K. Molnar-Kimber,et al.  Modulation of TNFα and IL-1β from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors , 2005, Agents and Actions.

[40]  M. Feldmann,et al.  Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. , 2003, Nature medicine.

[41]  J. Seyer,et al.  Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. , 1995, Autoimmunity.

[42]  K. Molnar-Kimber,et al.  Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. , 1993, Agents and actions.